Severe congenital neutropenia (SCN) was first described just over 50 years ago. The
progress in elucidating the clinical features and molecular pathophysiology of SCN closely …

Opinion statement Aging is the most potent of carcinogens, especially for the bone marrow
stem cell clonal disorders called myelodysplastic syndromes (MDS). Age-associated …

Myelodysplasia must be considered in the differential diagnosis of patients who have bone
marrow failure, but bone marrow cellularity per se may not substantially affect either …

Here we report the discovery of ON044580, an α-benzoyl styryl benzyl sulfide that
possesses potent inhibitory activity against two unrelated kinases, JAK2 and BCR-ABL, and …

Over the past decade, enormous progress has been made in the understanding of severe
congenital neutropenia (SCN), by identification of several causal gene mutations: in ELANE …

Granulocyte colony-stimulating factor (GCSF) drives the production of myeloid progenitor
and precursor cells toward neutrophils via the GCSF receptor (GCSFR, gene name CSF3R) …

Abstract Three annotated CSF3R mRNA splice variants have been described. CSF3R-V1 is
the wild-type receptor, while CSF3R-V4 is a truncated form increased in some patients with …

The cytokine G-CSF stimulates myeloid progenitors and is routinely used to accelerate
neutrophil recovery in the treatment of hematological malignancy and blood or marrow …

Myelodysplastic Syndromes are oligo‐clonal stem cell disorders that are associated with
cytopenias in the peripheral blood. Major causes for morbidity and mortality in …

As peripheral blood has surpassed bone marrow as a predominant source of stem cells for
transplantation, use of the cytokine granulocyte colony-stimulating factor (G-CSF) to mobilize …